Streetbeat News

Earnings

RAIN

Rain Oncology (NASDAQ:RAIN) reported Q3 losses of $(0.19) per share, beating the analyst consensus estimate of $(0.27) by 29.63%. This represents a 72.06% increase over losses of $(0.68) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:49 pm

VTGN

VistaGen Therapeutics reported Q2 2024 earnings per share (EPS) of $(0.66), beating the analyst consensus estimate of $(0.68) by 2.94%. This is a 72.5% increase over the same period last year. The company also reported quarterly sales of $277.70K, beating the analyst consensus estimate of $180.00K by 54.28%, a 131.11% increase over the same period last year.

Portfolio Pulse from totan@benzinga.com

November 09, 2023 | 9:49 pm

ONCT

Oncternal Therapeutics reported Q3 losses of $(0.17) per share, missing the analyst consensus estimate of $(0.14) by 21.43%. However, the company's quarterly sales of $179.00K beat the analyst consensus estimate of $120.00K by 49.17%. This represents a 19.05% increase in losses and a 53.14% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:48 pm

ORGO

Organogenesis has reported its Q3 earnings per share (EPS) at $0.02, with net revenue of $108.5M, which is lower than the estimated $111.4M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:48 pm

CTSO

CytoSorbents (NASDAQ:CTSO) reported Q3 2023 earnings per share (EPS) of $(0.21), missing the analyst consensus estimate of $(0.12) by 75%. The company also reported quarterly sales of $8.81 million, missing the estimate of $9.49 million by 7.15%. However, both EPS and sales showed an increase compared to the same period last year.

Portfolio Pulse from totan@benzinga.com

November 09, 2023 | 9:48 pm

SNES

SenesTech reported Q3 2023 GAAP EPS of $(0.47), beating the estimate of $(0.85) by 44.71%. However, the company's sales of $360.00K missed the estimate of $570.00K by 36.84%. Despite the miss, this represents a 44.00% increase in sales compared to the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 09, 2023 | 9:48 pm

EVBG

Everbridge reported Q3 earnings of $0.46 per share, beating the analyst consensus estimate of $0.42 by 9.52%. This is a 70.37% increase from the same period last year. The company also reported quarterly sales of $114.19 million, beating the estimate of $113.73 million by 0.41%. This is a 2.50% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:47 pm

PX

P10 (NYSE:PX) reported Q3 adjusted earnings of $0.20 per share, beating the analyst consensus estimate of $0.18 by 11.11%. However, this is a 4.76% decrease from the same period last year. The company's quarterly sales were $58.94 million, missing the analyst consensus estimate of $59.73 million, but showing a 17.89% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:47 pm

PEGY

Pineapple Energy (NASDAQ:PEGY) reported Q3 2023 earnings per share (EPS) of $(0.23), missing the analyst consensus estimate of $(0.08) by 187.5%. The company also reported quarterly sales of $18.29 million, missing the estimate of $20.60 million by 11.22%. However, these figures represent an increase over the same period last year, with EPS up by 32.35% and sales up by 137.24%.

Portfolio Pulse from totan@benzinga.com

November 09, 2023 | 9:46 pm

LIFE

aTyr Pharma reported Q3 losses of $(0.20) per share, beating the analyst consensus estimate of $(0.23) by 13.04%. However, the company's quarterly sales of $353.00K missed the analyst consensus estimate of $1.50M by 76.47%.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:46 pm